Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens

被引：0
|
作者：
Chakraborty, Rajshekhar [1 ,2 ]
Zanwar, Saurabh [3 ]
Bhutani, Divaya [1 ]
Gertz, Morie [3 ]
Dispenzieri, Angela [3 ]
Kumar, Shaji [3 ]
D'Souza, Anita [4 ]
Patwari, Anannya [4 ]
Cowan, Andrew [5 ]
Chen, GuiZhen [5 ]
Hegenbart, Ute [6 ]
Schoenland, Stefan [6 ]
Milani, Paolo [7 ]
Palladini, Giovanni [7 ]
Sanchorawala, Vaishali [8 ]
Bodanapu, Geethika [9 ]
Lentzsch, Suzanne [1 ]
Muchtar, Eli [3 ]
机构：
[1] Columbia Univ, New York, NY USA
[2] Columbia Univ, Irving Med Ctr, New York, NY USA
[3] Mayo Fdn Med Educ & Res, Scottsdale, AZ USA
[4] Med Coll Wisconsin, Milwaukee, WI USA
[5] Univ Washington, Seattle, WA USA
[6] Heidelberg Univ, Heidelberg, Germany
[7] Univ Pavia, Pavia, Italy
[8] Boston Med Ctr, Boston, MA USA
[9] Boston Univ, Boston, MA USA
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2024年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
35
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 16 条
  • [1] IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS
    Cavo, M.
    Palumbo, A.
    Bringhen, S.
    Di Raimondo, F.
    Patriarca, F.
    Rossi, D.
    Levi, A.
    Offidani, M.
    Montefusco, V.
    Narni, F.
    Zambello, R.
    Benevolo, G.
    Grasso, M.
    Falcone, A.
    Musto, P.
    Guglielmelli, T.
    Gherlinzoni, F.
    Gottardi, D.
    Musolino, C.
    Di Renzo, N.
    Masini, L.
    Cangialosi, C.
    Dore, F.
    Ballanti, S.
    Storti, S.
    Angelucci, E.
    Vallone, R.
    Magarotto, V.
    Morabito, F.
    Tosi, P.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 451 - 451
  • [2] Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis
    Kastritis, Efstathios
    Wechalekar, Ashutosh D.
    Dimopoulos, Meletios A.
    Merlini, Giampaolo
    Hawkins, Philip N.
    Perfetti, Vittorio
    Gillmore, Julian D.
    Palladini, Giovanni
    BLOOD, 2008, 112 (11) : 321 - 321
  • [3] Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens
    Lim, Sung Won
    Park, Song Ee
    Cho, Jangho
    Kim, Youjin
    Lee, Hansang
    Hong, Juhyun
    Jeon, Eunseok
    Choi, Jinoh
    Lee, Gayeon
    Kim, Byungjun
    Min, Ju Hong
    Kim, Jung Sun
    Lee, Jung Eun
    Choi, Joon Young
    Park, Silvia
    Kim, Seok Jin
    Jang, Jun Ho
    Kim, Won Seog
    Jung, Chul Won
    Kim, Kihyun
    BLOOD, 2017, 130
  • [4] Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies
    Fotiou, Despina
    Theodorakakou, Foteini
    Gavriatopoulou, Maria
    Migkou, Magdalini
    Malandrakis, Panagiotis
    Ntanasis-Stathopoulos, Ioannis
    Kanellias, Nikolaos
    Papaiakovou, Evangelos Eleutherakis
    Terpos, Evangelos
    Papanikolaou, Asimina
    Gakiopoulou, Charikleia
    Dimopoulos, Meletios Athanasios
    Kastritis, Efstathios
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 271 - 278
  • [5] Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis
    Bazarbachi, Abdul-Hamid
    Bhutani, Divaya
    Radhakrishnan, Jai
    Mapara, Markus
    Maurer, Mathew S.
    Lentzsch, Suzanne
    Chakraborty, Rajshekhar
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (11) : 2225 - 2228
  • [6] Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime
    Bomsztyk, Joshua
    Ravichandran, Sriram
    Khwaja, Jahanzaib
    Cohen, Oliver
    Rauf, Muhammad U.
    Foard, Darren
    Martinez-Naharro, Ana
    Venneri, Lucia
    Whelan, Carol
    Fontana, Marianna
    Hawkins, Philip N.
    Gillmore, Julian
    Lachmann, Helen
    Mahmood, Shameem
    Wechalekar, Ashutosh D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (01) : 138 - 145
  • [7] Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program
    Chakraborty, Rajshekhar
    Bhutani, Divaya
    Mapara, Markus
    Reshef, Ran
    Maurer, Mathew S.
    Radhakrishnan, Jai
    Lentzsch, Suzanne
    BLOOD, 2023, 142
  • [8] Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
    Bochtler, Tilmann
    Hegenbart, Ute
    Kunz, Christina
    Granzow, Martin
    Benner, Axel
    Seckinger, Anja
    Kimmich, Christoph
    Goldschmidt, Hartmut
    Ho, Anthony D.
    Hose, Dirk
    Jauch, Anna
    Schoenland, Stefan O.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1371 - +
  • [9] Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity
    Shah, Gunjan L.
    Kaul, Esha
    Fallo, Shelly
    Cossor, Furha I.
    Smith, Hedy
    Klein, Andreas K.
    Miller, Kenneth B.
    Comenzo, Raymond L.
    BLOOD, 2012, 120 (21)
  • [10] Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy
    Wong, S. W.
    Larivee, D.
    Warner, M.
    Sprague, K. A.
    Fogaren, T.
    Comenzo, R. L.
    BONE MARROW TRANSPLANTATION, 2017, 52 (06) : 936 - 937
12